Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

home / authors / ray-mcdermott-mb-bch-bao-phd-mba-frcpi

Articles

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, of the University College Dublin

Dr. McDermott on Preventing Recurrence of High-Risk Prostate Cancer

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
October 21st 2020

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Read More

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

Dr. McDermott on the Design of the DASL-HiCAP Trial in High-Risk Prostate Cancer

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
October 16th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.

Read More

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

Dr. McDermott on the Next Steps of the DASL-HiCAP Trial in High-Risk Prostate Cancer

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
October 12th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.

Read More

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
September 30th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need